Please assess the completion status of the following clinical trial:

Trial Title: Sorafenib Treatment in Patients With Hepatocellular Carcinoma With Microvascular Invasion After Radical Resection

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 18-75 years~2. Hepatocellular carcinoma confirmed by pathology~3. No macroscopic tumor thrombus vascular invasion and distant metastasis~4. R0 resection（clean resection margin both macroscopically and microscopically）~5. MVI confirmed by pathology~6. ECOG 0-1~7. Child-Pugh stage A~8. WBC \> 3×10E9/L；HB \> 90 G/L；PLT \> 50×10E9/L~9. ALT，AST not exceeding 5 times of the upper limit of normal value；CRE，TBIL not exceeding 1.5 times of the upper limit of normal value~Exclusion Criteria:~1. Tumor rupture or invading to adjacent organs~2. Patients who underwent liver transplantation~3. Past history of or simultaneously receiving other anti-cancer therapy (such as TACE, chemotherapy, radiotherapy and others）and immune cell infusion therapy~4. Uncontrolled cardiovascular and cerebrovascular diseases~5. History of gastrointestinal bleeding within 6 months~6. Active infection other than HBV, HCV~7. Postoperative complications, not suitable to take Sorafenib (such as long term use of drainage due to bile leakage, poor wound healing and others)~8. Confirmed liver cancer recurrence or metastasis within 4 weeks after hepatectomy~9. Poor compliance, cannot adhere to regular follow up~10. Diagnosed with other original malignant tumors other than HCC

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Sorafenib (Type: EXPERIMENTAL): Sorafenib (Nexavar) 200mg tablet, 2 tablets oral daily for 2 years, starting within 4weeks after hepatectomy. Regular treatment combined.
- Control (Type: NO_INTERVENTION): No use of Sorafenib (Nexavar). Regular treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).